Tonix TONMYA Sales Reach $15 Million After Medicare Deals

The Tip Desk · November 9, 2026 · 3 min read

TONMYA net sales were about $15 million in the third quarter, up 37% from $11 million, as covered lives reached about 166 million.

Tonix Pharmaceuticals Holding Corp. (TNXP), a commercial-stage biopharmaceutical company, reported TONMYA net sales of approximately $15 million for the quarter ended September 30, 2026, up 37% from about $11 million in the second quarter.

Total prescriptions rose 28% quarter-over-quarter to 16,375, after a 100% increase to 12,592 in the second quarter. New prescriptions increased 17% and refills 56%. President and Chief Executive Officer Seth Lederman, M.D., said total prescriptions, new prescriptions, and refills all increased, and that expanded payer access contributed to third-quarter sales growth.

Coverage was the commercial inflection. TONMYA covered lives expanded to approximately 166 million, or about 53% of the roughly 314 million covered lives in the United States, from about 136 million, or 43%, in the second quarter. In July the company announced a managed Medicare agreement adding about nine million Medicare lives; in September it announced a second adding about 21 million. On September 1 it added 50 representatives, completing a planned build to about 150 sales representatives. Lederman said the company had seen promising growth in key performance indicators since that expansion.

Net product revenue for the third quarter was approximately $17.2 million, compared with $3.3 million a year earlier, and consisted of combined net sales of TONMYA, Zembrace SymTouch, and Tosymra. Net revenue from Zembrace SymTouch and Tosymra was approximately $2.2 million, compared with $3.3 million in the same quarter of 2025.

Cost of sales was approximately $1.3 million, compared with $1.4 million a year earlier; the company attributed the decrease to a change in product mix. Research and development expenses were approximately $25.8 million, compared with $9.3 million. The company said the $16.5 million increase was primarily attributable to higher manufacturing expenses of $9.8 million, clinical expenses of $3.6 million, non-clinical expenses of $1.1 million, and employee-related costs of $1.5 million as it advanced its pipeline. Selling, general, and administrative expenses were approximately $45.6 million, compared with $25.7 million. The company said the $19.9 million increase primarily reflected commercialization after the November 2025 TONMYA launch, including higher sales and marketing expenses of $13.5 million, employee-related expenses of $4.1 million, and professional expenses of $1.5 million.

Net loss available to common stockholders was $53.3 million, or $2.89 a share, compared with $32.0 million, or $3.59 a share, a year earlier. Weighted average shares outstanding were 18,440,773.

Cash and cash equivalents were approximately $163 million as of September 30, 2026, compared with about $207.6 million at year-end 2025. Net cash used in operating activities was approximately $125.6 million for the nine months ended September 30, 2026, compared with about $60.2 million for the same period in 2025. The company said cash on hand, together with about $1.5 million raised from equity offerings after September 30, will meet operating and capital expenditure requirements into the early third quarter of 2027.

On October 2, Tonix disclosed that Dr. Reddy’s Laboratories had filed an Abbreviated New Drug Application with a Paragraph IV patent certification for a generic version of TONMYA. The company said it intends to enforce its intellectual property rights and cannot predict the outcome.

Enrollment is ongoing in HORIZON, a potentially pivotal Phase 2 study of TNX-102 SL in major depressive disorder. For TNX-4800, the company said the adaptive Phase 2 TRAIL field study is expected to begin in the first quarter of 2027 pending final FDA agreement, and that it is on track to deliver investigational product to study sites then. An investigator-initiated Phase 2 study of TNX-1500 at Massachusetts General Hospital is expected to initiate in the first quarter of 2027.